These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15287862)

  • 1. Increased levels of tissue inhibitor of metalloproteinase-1 in human hepatocellular carcinoma.
    Matsumoto E; Nakatsukasa H; Nouso K; Kobayashi Y; Nakamura S; Suzuki M; Takuma Y; Tanaka H; Fujikawa T; Shiratori Y
    Liver Int; 2004 Aug; 24(4):379-83. PubMed ID: 15287862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular distribution of transcripts for tissue inhibitor of metalloproteinases 1 and 2 in human hepatocellular carcinomas.
    Nakatsukasa H; Ashida K; Higashi T; Ohguchi S; Tsuboi S; Hino N; Nouso K; Urabe Y; Kinugasa N; Yoshida K; Uematsu S; Ishizaki M; Kobayashi Y; Tsuji T
    Hepatology; 1996 Jul; 24(1):82-8. PubMed ID: 8707287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of matrix metalloproiteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue, compared with the surrounding non-tumor tissue.
    Matsunaga Y; Koda M; Murawaki Y
    Res Commun Mol Pathol Pharmacol; 2004; 115-116():143-50. PubMed ID: 17564313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of a high activity of matrix metalloproteinase-9 to low levels of tissue inhibitors of metalloproteinase-1 and -3 in human hepatitis B-viral hepatoma cells.
    Kim JR; Kim CH
    Int J Biochem Cell Biol; 2004 Nov; 36(11):2293-306. PubMed ID: 15313474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of TIMP-1 mediated by recombinant adenovirus in hepatocellular carcinoma cells inhibits proliferation and invasion in vitro.
    Xia D; Yan LN; Xie JG; Tong Y; Yan ML; Wang XP; Zhang MM; Zhao LY
    Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):409-15. PubMed ID: 16911941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver expression of matrix metalloproteases and their inhibitors in hepatocellular carcinoma.
    Altadill A; Rodríguez M; González LO; Junquera S; Corte MD; González-Dieguez ML; Linares A; Barbón E; Fresno-Forcelledo M; Rodrigo L; Vizoso FJ
    Dig Liver Dis; 2009 Oct; 41(10):740-8. PubMed ID: 19372066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
    Zhou Q; Liang LJ; Peng BG; Zhen YY
    Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma.
    Yao DF; Wu XH; Zhu Y; Shi GS; Dong ZZ; Yao DB; Wu W; Qiu LW; Meng XY
    Hepatobiliary Pancreat Dis Int; 2005 May; 4(2):220-6. PubMed ID: 15908319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. X-linked inhibitor of apoptosis (XIAP) and XIAP-associated factor-1 expressions and their relationship to apoptosis in human hepatocellular carcinoma and non-cancerous liver tissues.
    Sakemi R; Yano H; Ogasawara S; Akiba J; Nakashima O; Fukahori S; Sata M; Kojiro M
    Oncol Rep; 2007 Jul; 18(1):65-70. PubMed ID: 17549347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
    Vivarelli M; Cucchetti A; La Barba G; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
    Ann Surg; 2008 Nov; 248(5):857-62. PubMed ID: 18948815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].
    Wu FS; Zheng SS; Wu LJ; Ding W; Ma ZM; Wang ZM; Teng LS; Zhao WH
    Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):603-8. PubMed ID: 16784653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis.
    Cucchetti A; Vivarelli M; Piscaglia F; Nardo B; Montalti R; Grazi GL; Ravaioli M; La Barba G; Cavallari A; Bolondi L; Pinna AD
    J Hepatol; 2005 Aug; 43(2):310-6. PubMed ID: 15970351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma.
    Lee YC; Pan HW; Peng SY; Lai PL; Kuo WS; Ou YH; Hsu HC
    Eur J Cancer; 2007 Mar; 43(4):736-44. PubMed ID: 17267202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-myc downstream regulated gene 1 (NDRG1)/Cap43 enhances portal vein invasion and intrahepatic metastasis in human hepatocellular carcinoma.
    Akiba J; Ogasawara S; Kawahara A; Nishida N; Sanada S; Moriya F; Kuwano M; Nakashima O; Yano H
    Oncol Rep; 2008 Dec; 20(6):1329-35. PubMed ID: 19020710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
    Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
    Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma.
    Lin SY; Pan HW; Liu SH; Jeng YM; Hu FC; Peng SY; Lai PL; Hsu HC
    Clin Cancer Res; 2008 Aug; 14(15):4814-20. PubMed ID: 18676753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of MT3-MMP in hepatocellular carcinoma correlates with capsular invasion.
    Arai I; Nagano H; Kondo M; Yamamoto H; Hiraoka N; Sugita Y; Ota H; Yoshioka S; Nakamura M; Wada H; Damdinsuren B; Kato H; Marubashi S; Miyamoto A; Takeda Y; Dono K; Umeshita K; Nakamori S; Wakasa K; Sakon M; Monden M
    Hepatogastroenterology; 2007; 54(73):167-71. PubMed ID: 17419254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of des-gamma-carboxy prothrombin levels in cancer and non-cancer tissue in patients with hepatocellular carcinoma.
    Yuan LW; Tang W; Kokudo N; Sugawara Y; Karako H; Hasegawa K; Aoki T; Kyoden Y; Deli G; Li YG; Makuuchi M
    Oncol Rep; 2004 Aug; 12(2):269-73. PubMed ID: 15254687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C.
    Shimoda M; Ghobrial RM; Carmody IC; Anselmo DM; Farmer DG; Yersiz H; Chen P; Dawson S; Durazo F; Han S; Goldstein LI; Saab S; Hiatt J; Busuttil RW
    Liver Transpl; 2004 Dec; 10(12):1478-86. PubMed ID: 15558585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of insulin-like growth factor-II, matrix metalloproteinases, and their tissue inhibitors as predictive markers in the peripheral blood of HCC patients.
    El Tayebi HM; Salah W; El Sayed IH; Salam EM; Zekri AR; Zayed N; Salem ES; Esmat G; Abdelaziz AI
    Biomarkers; 2011 Jun; 16(4):346-54. PubMed ID: 21506705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.